Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $54.00 Consensus Price Target from Analysts

Key Points

• Arcturus Therapeutics Holdings Inc. has received a consensus rating of "Buy" from nine brokerages, with eight analysts recommending a buy and one a strong buy, reflecting positive sentiment about the company's prospects.
• The average twelve-month target price for Arcturus stock is $54.00, indicating potential growth from its current trading price of $12.21.
• Several hedge funds have significantly increased their stakes in the company, highlighting strong institutional interest and confidence in Arcturus' market position.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has received an average recommendation of "Buy" from the nine ratings firms that are covering the firm, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $54.00.

ARCT has been the subject of several research analyst reports. Scotiabank reiterated an "outperform" rating on shares of Arcturus Therapeutics in a research report on Wednesday, July 2nd. Wells Fargo & Company cut their price target on Arcturus Therapeutics from $50.00 to $45.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. Citigroup restated a "buy" rating on shares of Arcturus Therapeutics in a report on Tuesday, May 13th. Wall Street Zen upgraded Arcturus Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. Finally, Canaccord Genuity Group decreased their price target on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th.

Institutional Trading of Arcturus Therapeutics

Hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP boosted its holdings in Arcturus Therapeutics by 0.8% in the fourth quarter. Wellington Management Group LLP now owns 97,036 shares of the biotechnology company's stock worth $1,647,000 after purchasing an additional 742 shares during the period. Ameriprise Financial Inc. grew its position in Arcturus Therapeutics by 5.0% in the 4th quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company's stock valued at $316,000 after buying an additional 883 shares in the last quarter. Tocqueville Asset Management L.P. increased its stake in shares of Arcturus Therapeutics by 4.5% during the first quarter. Tocqueville Asset Management L.P. now owns 23,400 shares of the biotechnology company's stock valued at $248,000 after acquiring an additional 1,000 shares during the period. Virtus ETF Advisers LLC raised its stake in shares of Arcturus Therapeutics by 38.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock worth $69,000 after buying an additional 1,132 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Arcturus Therapeutics by 9.2% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 14,693 shares of the biotechnology company's stock valued at $156,000 after acquiring an additional 1,232 shares during the last quarter. Institutional investors and hedge funds own 94.54% of the company's stock.

Arcturus Therapeutics Stock Performance

Shares of Arcturus Therapeutics stock traded down $0.07 during trading on Thursday, reaching $11.91. The company's stock had a trading volume of 396,324 shares, compared to its average volume of 359,176. The firm has a market cap of $323.00 million, a PE ratio of -4.71 and a beta of 2.26. The company has a 50-day moving average price of $13.15 and a two-hundred day moving average price of $13.31. The company has a current ratio of 5.64, a quick ratio of 5.64 and a debt-to-equity ratio of 0.06. Arcturus Therapeutics has a fifty-two week low of $8.04 and a fifty-two week high of $25.88.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($1.58) by $1.06. Arcturus Therapeutics had a negative return on equity of 27.41% and a negative net margin of 47.47%. The business had revenue of $29.38 million during the quarter, compared to analysts' expectations of $25.64 million. On average, analysts forecast that Arcturus Therapeutics will post -2.22 EPS for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.